Fragile X syndrome is the most frequent cause of intellectual disability in males, affecting 1 out of 3600 boys born. For the first time, researchers at Whitehead Institute have restored activity to the fragile X syndrome gene in affected neurons using a modified CRISPR/Cas9 system they developed that removes the methylation—the molecular tags that keep the mutant gene shut off—suggesting that this method may prove to be a useful paradigm for targeting diseases caused by abnormal methylation.
Research by the lab of Whitehead Institute Founding Member Rudolf Jaenisch, which is described online this week in the journal Cell, is the first direct evidence that removing the methylation from a specific segment within the FMR1 locus can reactivate the gene and rescue fragile X syndrome neurons.
The FMR1 gene sequence includes a series of three nucleotide (CGG) repeats, and the length of these repeats determines whether or not a person will develop fragile X syndrome: A normal version of the gene contains anywhere from 5-55 CGG repeats; versions with 56-200 repeats are considered to be at a higher risk of generating some of the syndrome’s symptoms; and those versions with more than 200 repeats will produce fragile X syndrome.
Until now, the mechanism linking the excessive repeats in FMR1 to fragile X syndrome was not well understood. But Shawn Liu, a postdoctoral researcher in Jaenisch’s lab and first author of the Cellstudy, and others thought that the methylation blanketing those nucleotide repeats might play an important role in shutting down the gene’s expression.
In order to test this hypothesis, Liu removed the methylation tags from the FMR1 repeats using a CRISPR/Cas9-based technique recently developed by him and Hao Wu, a former postdoctoral researcher in the Jaenisch lab. This technique can either add or delete methylation tags from specific stretches of DNA. Removal of the tags revived the FMR1 gene’s expression to the level of the normal gene.
“These results are quite surprising—this work produced almost a full restoration of wild type expression levels of the FMR1 gene,” says Jaenisch, who is a professor of biology at Massachusetts Institute of Technology and the senior author on the study. “Often when scientists test therapeutic interventions, they only achieve partial restoration, so these results are substantial.”
The reactivated FMR1 gene rescues neurons derived from fragile X syndrome induced pluripotent stem (iPS) cells, reversing the abnormal electrical activity associated with the syndrome. When rescued neurons were engrafted into the brains of mice, the FMR1 gene remained active in the neurons for at least three months, suggesting that the corrected methylation may be sustainable in the animal.
“We showed that this disorder is reversible at the neuron level,” says Liu. “When we removed methylation of CGG repeats in the neurons derived from fragile X syndrome iPS cells, we achieved full activation of FMR1.”
The CRISPR/Cas-9-based technique may also prove useful for other diseases caused by abnormal methylation including facioscapulohumeral muscular dystrophy and imprinting diseases.
“This work validates the approach of targeting the methylation on genes, and it will be a paradigm for scientists to follow this approach for other diseases,” says Jaenisch.
The Latest on: Fragile X syndrome
- Molecular site identified for targeted intervention of Fragile X syndrome on November 8, 2018 at 8:35 am
Researchers at The Hospital for Sick Children (SickKids) have identified the ion channel known as Kv1.2 as a new target for reducing certain Fragile X syndrome (FXS) symptoms. The research team, led b... […]
- Scholarship for education of Fragile X Syndrome on October 29, 2018 at 2:35 pm
Anita Nicholls is the recipient of a $10,000 AMP National Scholarship, which will allow her to pursue her dream of creating an education programme for parents of children with rare condition, Fragile ... […]
- Fragile X Syndrome - 2018 Pipeline Insight Report - ResearchAndMarkets.com on October 17, 2018 at 6:57 pm
DUBLIN--(BUSINESS WIRE)--The "Fragile X Syndrome - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering. This report offers a comprehensive insight of the pipelin... […]
- Fragile X Syndrome - 2018 Pipeline Insight Report - ResearchAndMarkets.com on October 17, 2018 at 4:35 am
The "Fragile X Syndrome - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering. This report offers a comprehensive insight of the pipeline (under development) the... […]
- A fragile existence on October 11, 2018 at 1:45 pm
Jair Triviño has fragile X syndrome and is nearing 60, but works exhausting hours collecting fruit in local fields. PHOTO: JUAN CRISTÓBAL COBO It's late afternoon in this tiny town tucked into the Col... […]
- US Fragile X Syndrome Market and Competitive Landscape - 2018 - ResearchAndMarkets.com on October 10, 2018 at 6:45 am
DUBLIN--(BUSINESS WIRE)--Oct 10, 2018--The "US Fragile X Syndrome Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering. US Fragile X Syndrome Market and ... […]
- Global Fragile X Syndrome Market and Competitive Landscape 2014-2018 & Forecast to 2023 - ResearchAndMarkets.com on October 9, 2018 at 4:51 am
DUBLIN--(BUSINESS WIRE)--The "Global Fragile X Syndrome Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering. Global Fragile X Syndrome Market and Compet... […]
- Fragile X Syndrome Market New Industry Research on Present situation & Future Growth forecast to 2025 on September 24, 2018 at 5:00 pm
This research report categorizes the global Fragile X Syndrome market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market ... […]
- What You Need to Know about Fragile X Syndrome on September 20, 2018 at 12:46 pm
Fragile X syndrome affects approximately 1 in 4,000 males and 1 in 6,000 females born in the United States. The genetic disorder is found in all ethnic groups. Experts estimate that around 1 in 800 ma... […]
- Neurotrope Enters into Collaboration with the Nemours / Alfred I. duPont Hospital for Children to Initiate a Clinical Trial in Fragile X Syndrome on September 4, 2018 at 5:00 pm
NEW YORK, Sept. 5, 2018 /PRNewswire/ -- Neurotrope Inc. (NTRP) a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative and neurodevelopmental disorders, including A... […]
via Google News and Bing News